Amgen Inc announced positive results of its pivotal Phase III trial for its denosumab drug for the treatment of osteoporosis. The results demonstrated that bone density at several skeletal sites improved for women in the early- and late-stage postmenopausal phase. Osteoporosis patients taking denosumab showed a drastic increase in lumbar spine bone mineral density (BMD) after 24 months, as compared to placebo, Amgen added.